Francesco Ricchetti
Overview
Explore the profile of Francesco Ricchetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
1360
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allegra A, Nicosia L, Rigo M, Bianchi N, Borgese R, Simone A, et al.
Technol Cancer Res Treat
. 2025 Jan;
24:15330338241297231.
PMID: 39865869
MR-guided radiotherapy (MRgRT) is novel treatment modality in Radiation Oncology that could allow a higher precision and tolerability of Radiation Treatments. This modality is possible due to dedicated systems consisting...
2.
Ruggieri R, Bianchi N, Gurrera D, Naccarato S, Borgese R, Simone A, et al.
Phys Med
. 2025 Jan;
130:104906.
PMID: 39842321
Purpose: Adaptive MRgRT by 1.5 T MR-linac requires independent verification of the plan-of-the-day by the primary TPS (Monaco) (M). Here we validated a Monte Carlo-based dose-check including the magnetostatic field,...
3.
Nicosia L, Allegra A, Giaj-Levra N, Bayani R, Darzikolaee N, Mazzola R, et al.
Clin Transl Radiat Oncol
. 2024 Jul;
48:100811.
PMID: 39036468
Aims: Evaluate effectiveness and safety of multiple HyperArc courses and patterns of progression in patients affected by BMs with intracranial progression. Methods: 56 patients were treated for 702 BMs with...
4.
Nicosia L, Ravelli P, Rigo M, Giaj-Levra N, Mazzola R, Pastorello E, et al.
Radiother Oncol
. 2023 Dec;
190:110043.
PMID: 38056694
Introduction: To evaluate prostate volume change during daily-adaptive prostate SBRT on 1.5 T MR-linac and to correlate it with treatment toxicity. Methods: a series of patients affected by low-to-intermediate risk...
5.
Pastorello E, Nicosia L, Cuccia F, Olivari L, Fiorini M, Giaj Levra N, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345138
Background And Purpose: Stereotactic body radiotherapy (SBRT) has a consolidated role in the treatment of bone oligometastases from prostate cancer (PCa). While the evidence for spinal oligometastases SBRT was robust,...
6.
Nicosia L, Mazzola R, Rigo M, Giaj-Levra N, Pastorello E, Ricchetti F, et al.
Radiol Med
. 2023 Apr;
128(5):612-618.
PMID: 37055672
Aim: This study aims to compare acute toxicity of prostate cancer (PCa) stereotactic body radiotherapy (SBRT) delivered by MR-guided radiotherapy (MRgRT) with 1.5-T MR-linac or by volumetric modulated arc (VMAT)...
7.
Cuccia F, Pastorello E, Vitale C, Figlia V, Giaj Levra N, Mazzola R, et al.
In Vivo
. 2023 Jan;
37(1):490-492.
PMID: 36593020
Background/aim: Sinonasal metastases arising from renal cell cancer are rare and usually managed with surgery. Few studies describe the use of radiotherapy in this specific setting, while the use of...
8.
Alongi F, Rigo M, Figlia V, Nicosia L, Mazzola R, Giaj Levra N, et al.
J Pers Med
. 2022 Dec;
12(12).
PMID: 36556203
The present study reports the preliminary outcomes in terms of adverse events and quality of life in the first 100 patients treated with 1.5T MR-guided daily-adaptive stereotactic body radiotherapy for...
9.
Nicosia L, Trapani G, Rigo M, Giaj-Levra N, Mazzola R, Pastorello E, et al.
J Clin Med
. 2022 Nov;
11(22).
PMID: 36431135
The aim of our study was to evaluate the efficacy and toxicity of a daily adaptive MR-guided SBRT on 1.5 T MR-linac in patients affected by lymph node oligometastases from...
10.
Nicosia L, Vitale C, Cuccia F, Figlia V, Giaj-Levra N, Mazzola R, et al.
Cancer Manag Res
. 2022 Sep;
14:2839-2846.
PMID: 36164468
Aim: To evaluate the impact of Ialuril soft Gels (HA) in reducing acute genito-urinary (GU) toxicity in patients treated with adjuvant or salvage radiotherapy for a prostate cancer relapse. Material...